COVANCE STRENGTHENS CENTRAL DIAGNOSTICS MANAGEMENT TEAM
Cardiographic expertise to prove cardiac safety of new compounds strengthened with key appointments |
|
Reno, Nevada, 10 September 2001 — Recognizing the key role that science plays in providing quality on-time results to its clients, Covance Inc. (NYSE: CVD) recently strengthened its management team in the rapidly growing area of Central Diagnostics. Central Diagnostics centralizes the collection, interpretation, and storage of ECGs and other diagnostic tests including images. These services offer customers systematic medical input into operational and management decisions during drug development enabling decisions to be made earlier on the fate of new compounds. Four key appointments expand Covance's ability to meet client needs.
Robert Lester, M.D. joined Covance's Central Diagnostic operations in June as a Medical Director with responsibility for leading the expanding team of full-time cardiology experts. His appointment rounds out the team, particularly reinforcing the Company's commitment to having every ECG read by a Board-Certified Cardiologist. Central Diagnostics service offerings are enhanced by his expertise in holter monitoring, echocardiography, and stress testing. "Bob brings experience from leading academic and clinical cardiology departments, including University of Pennsylvania and Duke University," said Daniel Goodman, M.D., Director, Medical Affairs and Scientific Innovation. "He is enhancing the Central Diagnostic team's pursuit of scientific innovation for proving the cardiac safety of new compounds."
Eileen Daniel has been appointed as Central Diagnostics Vice President, Global Operations, effective as of 1 August 2001. Eileen has been heading up Covance's European sales force where she focused on Central Laboratory and Central Diagnostic services over the past two years. She brings to her new role a global perspective on client desires for streamlined worldwide communication and operational efficiencies. "Eileen has helped grow this business over the past decade," said F. John Mills, M.D., Ph.D., President, Covance Clinical Support Services. "Her past involvement with Central Diagnostics and recent global experience bring a new and unique perspective."
John Raker has been appointed Regional Information Technology (IT) Director for US/Asia-Pacific operations for Central Laboratory Services. His responsibilities will include leading and managing the IT organization for Central Laboratory Services in Indianapolis along with the current IT staff for Central Diagnostics in Reno. John will play a key role in shaping the future IT organization for Central Diagnostics and Central Laboratory Services. John previously held technical and management positions at General Electric Medical Systems in Milwaukee, Wisconsin. During his 15 years at GE, he also managed the system and software development teams focused on developing state-of-the-art imaging systems in Computer Tomography (CT), Nuclear Medicine, and real-time Digital X-Ray.
Tony Butler joins the Central Diagnostics sales team as a lead Account Manager focused on clients who are based on the East Coast. Previously Manager Pricing/Sales Administration, he brings a strong knowledge of Central Diagnostics services, established relationships with clients, and an extensive knowledge of the industry.
Covance is uniquely positioned to expand its Central Diagnostics service offerings for the drug development industry through its close alignment with the Company's central laboratory — the world's largest central laboratory dedicated only to clinical trials.
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with 2000 pro forma revenues of $737 million, operations currently in 17 countries, and approximately 7,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through the website in the About Covance area.
Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings, revenue, earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts and other factors described in the Company's filings with the Securities and Exchange Commission. |
|
|
